TUSTIN, Calif., March 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today announced that senior management will present at the following upcoming investor conferences:
Peregrine will also present at the ROTH 22nd Annual OC Growth Stock Conference on Wednesday, March 17, 2010 at 12:30 pm PDT. The conference will be held at the Ritz-Carlton, Laguna Niguel. For more information about this conference, please visit: http://www.roth.com/main/Page.aspx?PageID=7226
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
CONTACT: Investors, GendeLLindheim BioCom Partners, 1-800-987-8256,
info@peregrineinc.com; or Media, Barbara Lindheim, +1-212-918-4650, both
for Peregrine Pharmaceuticals, Inc.
Web site: http://www.peregrineinc.com/
http://www.avidbio.com/
